Latest From Activate Immunotherapy
Having raised a precedent-setting $450m venture capital round in January 2015, Moderna is well on its way to a planned $600m additional fundraising. The privately held company is keeping quiet about what it's doing with all that cash. Tioma, Nutrina and Avelas are among other firms receiving VC financing.
The Sept. 19 meeting of FDA’s Vaccines and Related Biological Products Advisory Committee comes as several whole-cell cancer vaccines are in Phase III trials.
Gene Logic, part of the Indian genomics services company, Ocimum Biosolutions, has appointed Dr Norrie Russell as president. Dr Russell, who comes with more than 30 years of experience in drug discovery, has previously held leadership positions with NovaRx, Invitrogen, Aviva Biosciences and Lynx Therapeutics. He has also worked for AstraZeneca, where he was global head, biological science and technology.
Serbia is set to be the first European country to participate in NovaRx's pivotal Phase III clinical trial of its lead product candidate, Lucanix (belagenpumatucel-L), for the treatment of advanced non-small cell lung cancer (NSCLC).
- Therapeutic Areas
- NovaRx Corp.
- North America
- Parent & Subsidiaries
- Activate Immunotherapy
- Senior Management
Justin M Murdock, CEO
Fakhrai Habib, PhD, CSO
Todd M Binder, COO
Stella M Sung, PhD, CBO
- Contact Info
Phone: (858) 552-8600
6828 Nancy Ridge Dr.
San Diego, CA 92121
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.